Related Experiment Video
Updated: Jul 5, 2025
13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
7.9K
Kinase inhibitor pulldown assay (KiP) for clinical proteomics.
Alexander B Saltzman1, Doug W Chan2,3, Matthew V Holt2
1Mass Spectrometry Proteomics Core, Advanced Technology Cores, Baylor College of Medicine, Houston, TX, USA.
Clinical Proteomics
|January 15, 2024
Summary
This study introduces a novel mass spectrometry method, Kinase Inhibitor Pulldown coupled with Parallel Reaction Monitoring (KiP-PRM), for precise protein kinase quantification in cancer. This approach accurately profiles the kinome, aiding therapeutic decisions in breast cancer treatment.
Area of Science:
- Proteomics and Cancer Biology
- Mass Spectrometry-based Quantification
- Kinase Signaling in Oncology
Background:
- Protein kinases are crucial, often dysregulated, targets in cancer therapy.
- Current diagnostic methods like immunohistochemistry (IHC) for targets such as ERBB2 are semiquantitative.
- Accurate quantification of kinases is essential for effective cancer treatment decisions.
Purpose of the Study:
- To develop a highly sensitive and quantitative mass spectrometry assay for profiling the human kinome.
- To establish a method for accurate protein kinase quantification in limited clinical samples, such as biopsies.
- To enable simultaneous quantification of hundreds of kinases for comprehensive cancer profiling.
Main Methods:
- Kinase Inhibitor Pulldown (KiP) assays utilizing kinase inhibitors as a capture matrix.
- Optimization of KiP assays and development of a single-shot Parallel Reaction Monitoring (PRM) method for enhanced quantitative fidelity.
- Application of the KiP-PRM approach to patient-derived xenograft (PDX) models and human cancer biopsies, including the development of stable isotope labeled peptide standards.
Main Results:
- KiP assays successfully identified differentially expressed and biologically relevant kinases in PDX models.
- The optimized KiP-PRM method accurately quantified kinases in low-quantity human cancer biopsies.
- KiP-PRM profiling recapitulated intrinsic subtyping of PDX models and patient biopsies, correlating with transcriptomic data.
Conclusions:
- The KiP-PRM assay provides a sensitive and quantitative method for broad kinome profiling.
- This approach can accurately assess kinase expression in limited clinical samples, supporting precision medicine.
- The developed method offers a powerful tool for cancer diagnostics and therapeutic strategy development.
